Skin cancer vaccine next year, the birth of

"Nature" magazine recently reported that in Australia and the United Kingdom to treat common skin cancer vaccines have entered large-scale experimental stage.

Vaccines based on tumor targeting black. Melanoma is a deadly cancer, each year about 2% of new British hair cancers caused by melanoma. Black tumors are generally due to prolonged exposure to sunlight caused. Not timely treatment, the tumor can spread to other parts of the body.

Oxford, UK, Viagra is Austrian Institute of Molecular Medicine immunologist that although the melanoma was not caused by infection, the body's immune system is still
Ran to a certain extent, against cancer cells. He said that the black tumor cells to produce a specific protein (NY-ESO-1). The immune system can identify the protein, and if found to produce such proteins would be right to attack the tumor. However, when the tumor was found when the immune system is usually already too late.

This new vaccine is mainly synthetic protein, prompting the body's immune system early to start looking for the presence of tumors. The researchers injected the protein at the same time, also to the human body can promote the immune cells injected with the drug found in proteins. Ludeweixi Cancer Institute in Australia has conducted a small-scale tests. Test results are very satisfactory. The researchers at the resection in patients with carcinoma of the body after the injection to patients with this vaccine. The results show that vaccination of people with no vaccination, compared with the population, cancer recurrence rate of only one-third of the original.

Now Ludeweixi vaccine lab plans to conduct a larger scale clinical trials, this study relates to the UK and Australia, about 100 patients, testing will eventually be completed in 2005.

University of Birmingham Lawrence Young cancer researcher, said the use of chemical treatment of skin cancer, has been little effect, but exactly this type of cancer vaccine can replace chemical therapy, treatment of skin cancer, is particularly effective. Once the success of clinical trials, this vaccine can also be used to activate the protein is similar to other cancers, such as breast and prostate cancer.